On October 11, 2018, Barth, Martine; Contal, Sylvie published a patent.Recommanded Product: 142327-44-4 The title of the patent was Preparation of dioxobenzothiazolyl hydrazides as inhibitors of YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma. And the patent contained the following:
The invention relates to preparation of dioxobenzothiazolyl hydrazides of formula I as inhibitors of the YAP/TAZ-TEAD protein interaction. Compounds I wherein R1 is (un)substituted aryl; R2 is (un)substituted alkyl; R3-R6 each independently is halo, alkoxyl, alkylthio, etc.; R7 is H or alkyl, are claimed. Compounds I were evaluated for their biol. activities (data given). Compounds I are useful as inhibitors of the YAP/TAZ-TEAD interactions and can be used in treatment of cancers, such as malignant mesothelioma. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Recommanded Product: 142327-44-4
The Article related to dioxobenzothiazolyl hydrazide preparation yap taz tead interaction inhibitor antitumor, malignant mesothelioma treatment dioxobenzothiazolyl hydrazide preparation protein interaction inhibitor and other aspects.Recommanded Product: 142327-44-4
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics